Maprotiline (HCl)

Maprotiline (HCl) is a tetracyclic antidepressant (TeCA) that is used in the treatment of depression, with action and uses and adverse effects similar to imipramine. Its chemical name is N-methyl-9,10-ethanoanthracen-9(10H)-propylamine. Maprotiline (HCl) is administered orally.

Maprotiline (HCl) is primarily indicated in conditions like Depression.

Maprotiline (HCl) is contraindicated in conditions like Epilepsy, Mania, Myocardial infarction, Urinary retention (adynamic bladder),Narrow-angle glaucoma, Severe cardiovascular disorders, Acute recovery post-MI

The severe or irreversible adverse effects of Maprotiline (HCl), which give rise to further complications include Cholestatic jaundice, Grand-mal seizures, Agranulocytosis. The signs and symptoms that are produced after the acute overdosage of Maprotiline (HCl) include Coma, Seizures. The symptomatic adverse reactions produced by Maprotiline (HCl) are more or less tolerable and if they become severe, they can be treated symptomatically, these include Dizziness, Headache, Drowsiness, Palpitation, Tremors, Constipation, Skin rashes, Dry mouth, Hypotension, Faintness, Lethargy, Weakness, Blurred vision, Agitation, Insomnia.

Maprotiline should be used with caution (if it contains tartrazine) in patients with aspirin hypersensitivity, because it may produce allergic reaction (including bronchial asthma). Monitor ECG before initiating large doses. Avoid concurrent administration with electric shock therapy because may increase the hazards of therapy. Perform periodic leukocytes (white blood cells) counts and liver function tests. Photosensitization may occur so caution patients to take protective measures, sunscreen etc., against exposure to UV light or sun light. Following prolong therapy in high doses, abrupt discontinuation of maprotiline should be avoided because it may precipitate the symptoms of the cholinergic rebound such as nausea, vomiting or diarrhea etc. It should be used with extreme caution in case of pre-existing seizures, Parkinsonism, patient with respiratory depression and cardiac diseases. IM injection should be administered with caution in the patient receiving maprotiline. The drug should only be used during pregnancy if clearly needed.

Drug should not be given to Paediatrics, Pregnant Mothers, Cardiac / Hypertensive Patients, patients suffering from Kidney dysfunction, patients suffering from Liver Malfunction, and Neonates.If prescribing authority justifies the benefits of the drug against the possible damages he/she should reevaluate them and consult the reference material and previous studies.

25 mg (25 (25)) 24 hourly PO — Increase by 25 mg every 2 weeks upto 150-225 mg/day.

( ) — Not recommended in this age group

No neonatal dosage information is recorded for this medicine yet.

Maprotiline (HCl) is known to interact with other drugs, the details of drug interactions is as follows:DrugDetailsSeverityOnsetManagementAdrenalineAlcoholCoadministration result in additive central nervous system and impairment, thinking and psychomotor skills.ModeratePatient should be warned of interaction and advised to limit alcohol cosumption.Apraclonidine (HCl)Dopamine (HCl)Maprotiline blunt the pressor effect of dopamine.MinorNo especial precautions are necessary.EphedrineMaprotiline interfere with the pressor effect of ephedrine.MinorMonitor the patient`s blood pressure regularly.FurazolidoneCoadministration enhances the excessive serotonergic activity in CNS i.e. serotonin syndrome and may produce adverse effects like tremor,dizziness,myoclonus,diaphoresis,hyperthermia and coma.MajorCoadministration in general must not be used. If necessary 14 days gap must be given and both drugs started at low doses.Pimozidepimozide prolong QT interval result in increased risk of ventricular arrythmia,ventricular tachycardia and torsade de pointes because of arrhythmogenic potential related to their effect on cadiac conduction.Majorcocurrent use with other agent is considered contraindicated.Procarbazinecoadministration produce significant adverse reactions due to excessive serotonergic activity in the CNS i.e. serotonin syndrome.MajorCoadministration of these agents is considered contraindicated.There should be a gap of at least 14 days between initiation of treatment with maprotiline and discontinuation of maprotiline.Selegiline (HCl)Coadministration produce significant adverse reactions due to excessive serotonergic activity in the CNS i.e. serotonin syndrome.MajorCoadministration of these agents is considered contraindicated.There should be a gap of at least 14 days between initiation of treatment with maprotiline and discontinuation of maprotiline. Coadministration of these agents is considered contraindicated.There should be a gap of at least 14 days between initiation of treatment with maprotiline and discontinuation of maprotiline.Thioridazine (HCl)Thioridazine and maprotiline both prolong QT interval result in increasedrisk of ventricular arrythmia.MajorCoadministration of these agents is considered contraindicated.VORICONAZOLEAdditive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation These interactions are sometimes beneficial and sometimes may pose threats to life. Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Tab Store Below 40°C. Protect from Sunlight and Heat.